Abstract
In POSEIDON, a Phase 3 study (NCT03164616) of patients with EGFR/ALK wild-type metastatic NSCLC (mNSCLC), first-line tremelimumab + durvalumab + chemotherapy (T+D+CT) demonstrated statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) versus CT alone. CTLA-4 inhibition (T) supports T-cell expansion; PD-L1 inhibition (D) overcomes T-cell suppression at the tumour; and chemotherapy (CT) causes tumour cell death and antigen release, priming the immune response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
